Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,772 signal articles · 75 in last 24h · 148,324 total before filter · latest 55m ago
75last 24h
977last 7d
110● bullish (7d)
126● bearish (7d)
212publishers
AllMacro369Earnings115M&A98Regulatory8Product11Analyst12
✕ clear all filtersticker: MSFTsentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
Simply Wall St.2h agoneutral
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx’s commercial gene therapy portfolio and manufacturing footprint in the U.S. We’ll now explore how FAYUVI’s first-in-disease approval and the associated...

Bill Ackman's Pershing Square IPO Breaks Out
Investor's Business Daily4h agoneutral
Bill Ackman's Pershing Square IPO Breaks Out

Bill Ackman's Pershing Square Inc., a recent IPO, broke out past a buy point Friday in a rocky market.  The hedge fund billionaire's publicly traded investment vehicle, Pershing Square Inc., rallied an impressive 27% for the week after bullish analyst upgrades.

How Low Can UiPath Stock Go When Its Numbers Are Not The Problem?
Trefis18h agoneutral
How Low Can UiPath Stock Go When Its Numbers Are Not The Problem?

UiPath (PATH) trades at about $14, some 29% below its high of the past year, and it has lost 11.7% over the past month. Its results are not what did that. The fall is recent: the stock is still up 34.5% over the past three months, and over the past twelve months it returned 18.9% against 17.0% for the S&P 500. What matters is how far a stock like this falls in a real shock.

Is Palantir's Lead Over Its Peers Already Priced In?
Trefis22h agoneutral
Is Palantir's Lead Over Its Peers Already Priced In?

Palantir Technologies (PLTR) grew revenue faster over the past twelve months than every company in its peer group, and only one company in that group earns a wider operating margin. Palantir also carries the group's highest earnings multiple. Over those same twelve months the stock returned less than the S&P 500. The operational lead is evident, but current market valuations appear to price in much of that outperformance.

What Happens To Snowflake Stock If AI Keeps Costing It Margin?
Trefis1d agoneutral
What Happens To Snowflake Stock If AI Keeps Costing It Margin?

Snowflake (SNOW) has returned about 53% over the past year, and its product revenue growth has accelerated for three straight quarters. In early September, the company cut its fiscal 2027 non-GAAP product gross margin guide by a point, to 74%, pointing to a heavier mix of fast-growing AI workloads that carry a lower contribution margin. So what happens to the stock if that mix keeps shifting.

These Magnificent Seven Members Still Look Cheap
Zacks1d agoneutral
These Magnificent Seven Members Still Look Cheap

Microsoft's accelerating cloud growth and NVIDIA's unmatched hardware dominance in the AI era mean investors are getting rock-solid earnings power at multiples that look very reasonable relative to their long-term growth trajectories.

What Did Microsoft Tell You Before Its Stock Ran?
Trefis1d agoneutral
What Did Microsoft Tell You Before Its Stock Ran?

Microsoft (MSFT) stock has returned about 32% since mid-June 2026. The S&P 500 returned about 3% over the same window, and peers moved in both directions: Alphabet fell 4.5% while Apple returned 14.0%. Neither came close to Microsoft, so this was not a sector tide. It was one company, and Microsoft had spent three quarters explaining out loud how internal capacity allocation decisions had constrained Azure's reported growth.